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A defined antigen skin test for the diagnosis  
of bovine tuberculosis
Sreenidhi Srinivasan1,2, Gareth Jones3, Maroudam Veerasami1,4, Sabine Steinbach3, 
Thomas Holder3, Aboma Zewude5, Abebe Fromsa5, Gobena Ameni5,  
Laurel Easterling1,2, Douwe Bakker1,6, Nicholas Juleff7, Glen Gifford8, R. G. Hewinson9, 
H. Martin Vordermeier3,9, Vivek Kapur1,2*
Bovine tuberculosis (bTB) is a major zoonotic disease of cattle that is endemic in much of the world, limiting live-
stock productivity and representing a global public health threat. Because the standard tuberculin skin test pre-
cludes implementation of Bacille Calmette-Guérin (BCG) vaccine–based control programs, we here developed 
and evaluated a novel peptide-based defined antigen skin test (DST) to diagnose bTB and to differentiate infected 
from vaccinated animals (DIVA). The results, in laboratory assays and in experimentally or naturally infected ani-
mals, demonstrate that the peptide-based DST provides DIVA capability and equal or superior performance over 
the extant standard tuberculin surveillance test. Together with the ease of chemical synthesis, quality control, and 
lower burden for regulatory approval compared with recombinant antigens, the results of our studies show that 
the DST considerably improves a century-old standard and enables the development and implementation of crit-
ically needed surveillance and vaccination programs to accelerate bTB control.
INTRODUCTION
Tuberculosis, caused by Mycobacterium tuberculosis var. tuberculosis, 
is one of the world’s deadliest infectious diseases, claiming as 
many as three human lives every minute (1–3). The closely related 
M. tuberculosis var. bovis (M. bovis) is the main cause of tuberculosis in 
a wide variety of animal hosts, including cattle [bovine tuberculosis 
(bTB)], and considerably limits livestock productivity (4, 5). bTB 
represents a serious zoonotic threat and is estimated to cause ap-
proximately 10% of the total human tuberculosis cases worldwide 
(6–8). While bTB is well controlled in most high-income countries 
through the implementation of strict test and cull strategies, the dis-
ease remains endemic in most low- and middle-income countries, 
where national control programs have not yet been implemented 
for socioeconomic reasons, and hence continues to contribute major 
losses to animal productivity along with human morbidity and mor-
tality (9–12).
On the basis of an approach initially established more than a cen-
tury ago, the current standard for diagnosis of bTB in animals mea-
sures cell-mediated immune response following an intradermal skin 
test with the poorly defined and highly variable tuberculin skin test 
(TST) antigen (13, 14). More recently, an in vitro interferon- (IFN-) 
release assay (IGRA) has been introduced as an ancillary test to im-
prove the overall sensitivity of detection of bTB-infected animals 
(15, 16). The poorly standardized stimulating antigens in the TST 
[“purified protein derivative” (PPD)] are extracts obtained from the 
heat-killed cultures of specified strains of mycobacteria grown on 
glycerol broth (17, 18). For instance, bovine PPD (PPD-B) is de-
rived from an extract of M. bovis AN5 strain culture, while avian 
PPD (PPD-A) is a similarly prepared extract from M. avium subsp. 
avium D4ER (19). In regions with high exposure to environmental 
mycobacteria, the difference in increase in skin induration reaction 
between PPD-B and PPD-A is ascertained using the single intrader-
mal comparative cervical tuberculin test (SICCT) to improve test 
specificity but is known to reduce assay sensitivity (13). Furthermore, 
in addition to the poor standardization of the PPDs, the presence of 
cross-reactive antigens between the pathogenic and vaccine strains 
in the crude whole cell antigen preparation renders the PPD-based 
TST unable to differentiate infected from Bacille Calmette-Guérin 
(BCG)–vaccinated animals (DIVA), thereby limiting opportunities 
for the development of BCG vaccination–based control programs 
(20–23). Hence, there is a well-recognized and urgent need to develop 
defined antigen-based bTB diagnostic assays with DIVA capabili-
ties for use alongside future (vaccination- based) control programs 
in regions where conventional test and cull strategies are not feasi-
ble for socioeconomic reasons (24).
Over the past two decades, comparative genomic and transcrip-
tome analyses have identified several specific M. bovis antigens with 
DIVA capability, including ESAT-6, CFP-10, and Rv3615c that are 
present in field strains of M. bovis but are either absent or not im-
munogenic in the widely used vaccine strain, BCG (25, 26). When used 
in combination, these antigens have shown promise in both detect-
ing infected animals and differentiating them from those vaccinated 
with BCG, thereby paving the way for the development of a much- 
needed defined antigen skin test (DST) with DIVA capability (27).
Building on this promising earlier work, the aim of the current 
study was to develop and evaluate a peptide cocktail of minimum 
complexity as a defined skin test antigen with DIVA capability that 
might serve as a reliable, easy to produce, and fit-for-purpose assay 
for diagnosis of bTB. Last, a considerable advantage of peptide-based 
reagents is the potential for use under regulatory environments such 
as in India where genetically modified or recombinant proteins with 
synthetic tags either are not permitted or face a high threshold for 
approval. Our investigations suggest that this peptide-based DST not 
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only has equal or superior performance characteristics over the ex-
tant standard tuberculin surveillance test but also obviates many of 
the limitations of the current assays while enabling the development 
and implementation of critically needed vaccination programs to 
accelerate bTB control in high prevalence human and bTB settings 
where it is needed the most.
RESULTS
Defined antigens elicit a sensitive and specific in vitro IFN- 
and skin test response in bTB-infected cattle
A comparison of the performance of a peptide cocktail composed of 
40-mer peptides covering the sequences of ESAT-6, CFP-10, and 
Rv3615c with a 20-residue overlap [peptide cocktail–long (PCL)] 
and a recombinant fusion protein of the same three antigens was 
undertaken using IGRAs, with peripheral blood mononuclear cells 
(PBMCs) isolated from naturally M. bovis–infected cattle, naïve 
controls, and BCG vaccinates. The IGRAs were performed to estab-
lish a dose-response relationship, and the results were expressed as 
area under the curves (AUC; Fig. 1A). The data demonstrated that 
PCL induced significantly stronger in vitro IFN- responses in in-
fected cattle compared to the fusion protein (P = 0.0004; Fig. 1A). In 
contrast, both PCL and the fusion protein induced minimal, if any, 
IFN- responses in PBMCs from control or vaccinated animals, 
together suggesting potential utility of defined antigens in in vitro 
IFN- assays to specifically identify M. bovis–infected cattle (Fig. 1A). 
These data suggested that both DST reagents may also be applied 
to the blood test commonly used as ancillary test to skin testing 
in cattle.
The performances of PCL and the fusion protein as defined skin 
test antigens were next assessed in animals experimentally infected 
with M. bovis (n = 24). The results showed that when applying the 
established strict DST interpretation criteria of 2 mm or more in-
crease in skin induration reaction [using Receiver Operating Char-
acteristic (ROC) analyses to set this cutoff point], PCL was able to 
correctly classify all of the infected animals as positive, while the fu-
sion protein identified 23 of 24, although this difference was not sta-
tistically significant (P = 0.8401; Fig. 1B). In contrast, neither PCL 
nor fusion protein induced measurable skin induration responses 
in a control group of naïve animals (n = 20). Together, these results 
suggest that while PCL performs better than the fusion protein in 
IGRAs and equivalently in skin tests, they are both able to accurate-
ly classify infected from uninfected animals with high apparent sen-
sitivity and specificity.
A subset of peptides drives most of the observed immune 
responsiveness in infected cattle
Next, we performed extensive peptide mapping experiments to 
identify immune-dominant peptides within PCL in an attempt to 
develop a peptide cocktail of reduced complexity, containing only 
the most dominant and major histocompatibility complex (MHC)–
promiscuous recognized peptides. In addition, this provided an oppor-
tunity to identify individual 40-mer peptides that might be susceptible, 
for example, to inappropriate processing or other modifications that 
might lead to loss of immune recognition. To mitigate this potential 
risk, we mapped a set of shorter overlapping peptides described in a 
previous study (28), with the aim of identifying better responding 
shorter substitute peptides covering the same epitopic region. Individual 
Fig. 1. In vitro and skin test responses of fusion protein and PCL. (A) Capacity of antigens (Fusion and PCL) to induce in vitro IFN- response in PBMCs collected from natu-
rally M. bovis–infected cattle (n = 10), naïve cattle (n = 10), and BCG vaccinates (n = 10) was determined. The antigens were used at titrated dose concentrations, and AUC 
is plotted. The horizontal line provides the mean (±SD), and the statistical difference between the responses was determined by using two-tailed paired t test (**P < 0.01; 
***P < 0.001). The background-corrected optical density (OD) values of the Fusion and PCL at each titrated concentration tested are shown in the inset. The PPD-B–induced 
IGRA responses of these animals tested in (A) are shown in fig. S1. (B) Skin test responses for Fusion, PCL, and PPD(B-A) were measured at 72 hours after injection in cattle 
experimentally infected with M. bovis (n = 24) and naïve controls (n = 20). Results are expressed as the difference in skin thickness (in millimeters) between the pre- and 
post-skin test readings, with the horizontal line providing the median [±95% confidence interval (CI)]. The statistical difference between the responses was determined 
using analysis of variance (ANOVA) (****P < 0.0001). The solid horizontal lines at 2 and 4 mm are the cutoffs used for Fusion and PCL, and PPD(B-A) and PPD-B, respectively.
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peptides from PCL and of a corresponding set of overlapping short, 
16– to 20–amino acid–long peptides were synthesized and screened for 
their ability to elicit IFN- responses in Enzyme-linked immune ab-
sorbent spot (ELISpot) assays using PBMCs isolated from naturally 
M. bovis–infected cattle (n = 14). The results show that most of the 
observed immune responsiveness within PCL and the shorter pep-
tides are driven by only a subset of peptides recognized promiscu-
ously by almost every animal tested (Fig. 2). This result suggested 
that further refinement of the compositional complexity of PCL was 
possible. The data also suggest that some epitopes when contained 
within the long peptides were not as well recognized than when they 
were represented on the shorter peptides (Fig. 2). For example, a strong 
epitope within ESAT-6 is localized within the short peptide ES5. Con-
sequently, the expectation was that EL2 would be strong and promis-
cuously recognized as well. However, as Fig. 2 shows, peptide EL2 was 
poorly and infrequently recognized. Other similar examples also occurred 
with peptide CL1, which is poorly recognized, while the short peptide 
CS2, whose sequence is contained in CL1, is strongly recognized. Similarly, 
RL1 and RL3 were poorly recognized but their poor recognition could 
be compensated by the short peptides RS3 and RS6 (Fig. 2).
Optimized peptide cocktail PC-1 displays comparable 
sensitivity and specificity as PCL
On the basis of the strength of immune response induced by indi-
vidual peptide antigens and the sequence overlaps between PCL and 
shorter peptides, we assembled a cocktail [peptide cocktail 1 (PC-1)] 
representing a combination of promiscuously recognized long and 
short peptides (table S1). The capability of PC-1 to induce an IFN- 
response was assessed with IGRAs performed on cryopreserved 
PBMCs isolated from known naturally infected cattle (n = 20), 
naïve controls (n = 10), and BCG vaccinates (n = 10). The results 
showed that PCL induced a significantly stronger response in in-
fected animals compared to PC-1 (P < 0.001), although this was 
driven by a stronger response elicited by PCL at only the highest 
titrated dose concentration (10 g/ml), but not others (Fig. 3, inset). 
This high concentration also induced nonspecific IGRA responses 
in some of the naïve animals and is therefore not a peptide concen-
tration that is diagnostically relevant due to its relative lack of spec-
ificity. If this concentration was disregarded in calculating the 
AUCs, PCL and PC-1 performed identically (fig. S2A). Only limited, 
if any, IGRA responses based on evaluation of AUC values were in-
duced by either cocktail when they were tested with PBMCs from 
naïve or BCG-vaccinated animals (Fig. 3).
PCL demonstrates superior performance compared 
with conventional PPD-based assays in naturally infected 
cattle in an endemic country setting
To assess and compare the performance characteristics of PCL as a de-
fined skin test antigen with current PPD-based standards in crossbred 
cattle in endemic country settings, we tested PCL and PC-1 alongside 
Fig. 2. Heat map representing the IFN- response elicited by the individual long (top) and short (bottom) peptides of ESAT-6, CFP-10, and Rv3615c. ELISpot/
FluoroSpot assays were performed using PBMCs isolated from naturally M. bovis–infected cattle (n = 14). Z scores of individual peptide response are mapped. On the basis 
of overall peptide responder frequencies, a new peptide cocktail was formulated, PC-1. The peptides constituting PC-1 are marked with closed circles. Note: RL2 could not 
be synthesized due to technical difficulties, and RS5 was included as part of PCL to cover the gap in the overlap left by the absence of RL2.
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PPD-A and PPD-B in a naturally infected herd of Zebu cattle in 
Ethiopia (n = 25). The results showed that PPD-B, PCL, and PC-1 
identified 22, 19, and 17 animals, respectively, of 25 animals in this 
herd as infected (Fig. 4, A and B). PCL, PC-1, and PPD-B identified a 
greater number of infected animals compared to the SICCT, which 
only correctly classified 12 of 25 animals. The disappointing per-
formance of the SICCT in this herd is consistent with the observations 
that a high burden of exposure to environmental mycobacteria, as evi-
denced by the increase in skin thickness induced by PPD-A (Fig. 4A), 
is a well-known SICCT confounder reducing its sensitivity (13, 29, 30). 
In the herd tested, 10 of 22 PPD-B–positive animals tested SICCT neg-
ative due to a stronger response to PPD-A than PPD-B (Fig. 4A). Fur-
thermore, of the 13 animals that tested negative in the SICCT, 9 tested 
positive to PCL (Fig. 4C, open red circles), demonstrating that the 
majority (69%) of naturally infected animals missed by SICCT were 
detected by PCL (Fig. 4C). PCL also matched the number of positives 
obtained with the high sensitivity interpretation of SICCT (severe 
interpretation). Together, the suggestion of superior performance 
of PCL and PC-1 compared to SICCT presented in this study in a 
high-bTB burden herd with concurrent high levels of sensitization 
to environmental mycobacteria is encouraging and prioritizes them 
for further evaluations to accurately define their performance under 
field conditions.
DISCUSSION
Comparative genomic, transcriptomic, and proteomic analyses have 
identified several promising M. bovis antigens with DIVA capability 
including the highly immunogenic proteins ESAT-6, CFP-10, and 
Rv3615c that are present in M. bovis but either absent or not immu-
nogenic in all BCG vaccine strains (26, 27, 31–34). Used in combi-
nation as defined antigens, these proteins have shown considerable 
promise in detecting M. bovis–infected animals and in differentiating 
them from those vaccinated with BCG in both skin test and labora-
tory assays. Extending these data with recombinant protein-based 
DST, the results of the current study show that a fusion protein con-
taining these three antigens was able to induce specific skin test re-
sponses to detect infected cattle (Fig.  1). However, peptide-based 
reagents may have potential for use even in regions with high regu-
latory barriers for in vivo use of recombinant-derived products in 
food-producing animals, and our work described here using syn-
thetic peptides was undertaken to overcome the limitations on the 
use of recombinant proteins in such regulatory environments. Syn-
thetic peptide-based DST for bTB diagnosis has recently shown 
promise as an alternative to recombinant proteins (27, 31, 32, 35). 
However, these peptide cocktails were composed of large and com-
plex sets of short overlapping 16- to 20-mer peptides with limited 
commercial use as a skin test reagent due to cost challenges asso-
ciated with manufacture and quality assurance of complex peptide 
mixtures. To address these challenges, our current studies show that a 
less complex cocktail of 40-mer-long overlapping peptides (PCL) perform 
superior to the recombinant fusion protein in IGRA and equivalent 
in inducing skin responses in infected animals while maintaining 
the high specificity in naïve or BCG-vaccinated animals.
We attempted to reduce the complexity of the peptide cocktail 
by mapping the immunodominant peptides within PCL as well as a 
shorter set of overlapping peptides using ELISpot assays (Fig.  2). 
The findings suggest that while most of the PCL peptides were strongly 
recognized, a smaller subset appeared poorly antigenic for reasons 
that are not fully understood but may include steric hindrance in 
fitting of the peptides in the MHC binding groove or inappropriate 
processing (36, 37). For example, CL1 appeared to be poorly recog-
nized in ELISpot assays, while the short peptide CS2, whose sequence 
is located within CL1, was recognized promiscuously (Fig.  2). In 
contrast, a number of the long peptides, such as CL3 and CL4 on the 
C terminus of CFP-10, elicited a far stronger response than short pep-
tides CS6 to CS10 that cover the same region of the sequence. These 
observations highlight the opportunity to optimize and refine the 
cocktail composition by inclusion of combinations of immune- 
dominant long and short peptides that together elicited both broad 
and promiscuous responses.
To explore this possibility, a refined combination of peptide anti-
gens was designed (PC-1, table S1) and evaluated in vitro and in ani-
mal studies. The results showed a similar in vitro IFN- response of both 
PC-1 and PCL in reactor cattle (Fig. 3). Because studies performed under 
controlled experimental conditions often overestimate diagnostic test 
performance in comparison with field studies, we next sought to as-
sess the performance of the peptide cocktails under field conditions 
in a bTB endemic region. The results show that there is no significant 
difference in the proportion of animals testing positive to PC-1 and 
PCL in skin tests (Fig. 4B). Together, these data provide compelling 
evidence of the potential to reduce the complexity of the peptide 
cocktail even while further enhancing and optimizing performance 
characteristics by selecting the optimal combination of dominant 
long and short peptides for inclusion as a defined skin test antigen.
To assess performance characteristics in endemic country set-
tings, the relative sensitivity of the PCL and PC-1 peptide cocktails 
was assessed in a group of 25 naturally infected reactor crossbred 
Fig. 3. In vitro responses of PCL and PC-1. Capacity of PCL and PC-1 to induce 
in vitro IFN- responses in PBMCs collected from naturally M. bovis–infected cattle 
(n = 20), BCG vaccinates (n = 10), and controls (n = 10) was evaluated. The antigens 
were used at titrated dose concentrations, and AUC is plotted. The horizontal line 
provides the median (±95% CI), and the statistical difference between the respons-
es for reactors and controls was determined using the Wilcoxon matched-pairs 
signed-rank test (***P < 0.001; **P < 0.01), while two-tailed t test was used for vac-
cinates (**P < 0.01). There is no significant difference between the responses in-
duced by PCL and PC-1 in infected animals. The background-corrected OD values 
of PCL and PC-1 at each titrated concentration tested are shown in the inset, where 
PCL induced a significantly stronger response than PC-1 only at the highest titrated 
dose concentration of 10 g/ml. PPD-B–induced IGRA responses of these animals 
are shown in fig. S2B.
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cattle in Ethiopia. The results confirm that the relative diagnostic sen-
sitivity of the synthetic peptide cocktails (PCL and PC-1) did not sig-
nificantly differ from that of the Single Intradermal Test (SIT) (PPD-B) 
(Fig. 4B). In contrast, at 48%, the relative sensitivity of the PPD(B-A) 
response was 40% lower than that observed for PPD-B alone, sug-
gesting that in these animals the relative sensitivity of the widely used 
and The World Organization for Animal Health/Office International 
des Epizooties (OIE)–prescribed SICCT assay for endemic regions 
was significantly (P = 0.005; Fisher exact; two-tailed) lower than that 
of the SIT. While this finding is not altogether surprising, given the 
likely high burden of environmental mycobacteria in Ethiopia and 
other countries in which bTB remains endemic, it underscores the 
primary dilemma of tuberculin- based skin testing in bTB endemic 
countries with high or unknown burden of environmental myco-
bacteria: The use of PPD-B alone as in with the SIT often results in 
high rates of false-positive results due to sensitization with environ-
mental mycobacteria, and conversely, the comparative (SICCT) test 
has the potential for a high false-negative rate due to the masking of 
the PPD-B responses in animals sensitized with environmental my-
cobacteria (13, 29). In contrast, by using defined antigens, the DST 
has the potential to obviate many of the limitations of traditional 
tuberculin-based tests and also provides an opportunity to obtain 
diagnostic sensitivities equivalent to that of the SIT and specificities 
equal or exceeding the SICCT, all within a single injection site.
The results of this and other studies (27, 35) suggest that the use 
of defined antigens provides considerably lower amplitude of skin 
reactions in reactor animals (in this study: 8 ± 1.5 mm with PCL as 
compared with an average of 19.5 ± 3.5 mm with PPD-B) without 
compromising sensitivity. Furthermore, because the DST obviates 
the need for administration of PPD-A to improve test specificity, 
animals that are exposed to environmental mycobacteria that lack 
or do not express the DST antigens remain unreactive, providing a 
considerable technical advantage as well as animal welfare benefits 
when considering routine surveillance of animals in regions with 
high exposure to environmental mycobacteria.
While the DST shows considerable promise as a fit-for-purpose 
test for routine surveillance and diagnosis of bTB-infected animals, 
given the lack of concordance between the different tests used for 
bTB diagnosis under field conditions (Fig. 4 and fig. S4), it will be 
important for future studies to establish the true status of infection 
in field reactor animals to obtain robust estimates of test sensitivity 
or specificity. For instance, although all of the cattle included in our 
Fig. 4. Skin test response to peptide cocktails in field reactors. (A) Peptide cocktails, PCL and PC-1, alongside PPD-A and PPD-B, were tested in naturally infected ani-
mals identified in Ethiopia (n = 25). Results are expressed as the difference in skin thickness (in millimeters) between the pre- and post-skin test readings, with the hori-
zontal line providing the median (±95% CI). Positivity is defined as ≥2 mm for PCL and PC-1, and ≥4 mm for PPD(B-A) and PPD-B (denoted by the solid lines). The statistical 
difference between PCL and PC-1 responses was determined by using two-tailed t test (**P < 0.01). (B) The relative sensitivity of the peptide cocktails, SIT, and SICCT was 
calculated. (C) Animals represented by open red circles are positive by PCL only, closed blue circles are positive by PPD(B-A) only, open blue circles are negative on both, 
and closed red circles are positive on both. The peptide cocktail, PCL, identified nine (36%) presumed infected animals that were not detected by the standard SICCT.
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experiment in Ethiopia were presumably M. bovis–infected animals 
because they were part of a heavily infected herd and at the very 
least were highly exposed to M. bovis in their environment, their true 
infection status remains unknown without conducting a thorough 
postmortem examination, which is a challenge even in high-income 
country settings. Because of the lack of an accurate reference ante-
mortem test for infection, it is not surprising that trials for valida-
tion of tuberculosis diagnostics are difficult to perform under field 
conditions, particularly in endemic country settings (38, 39). To ad-
dress this issue, large-scale surveillance programs in endemic country 
settings combined with powerful statistical approaches including 
maximum likelihood estimation and Bayesian inferences will be re-
quired for accurate estimates of DST or TST performance and are 
planned. We note that although the 2-mm cutoff for DST applied in 
the current study was established using ROC analyses, this will need 
to be reassessed as additional data from field trials with the DST be-
come available to ensure optimal balance between sensitivity and 
specificity in relevant geographies to best meet local needs.
An important goal remaining in the field of bTB diagnostics is to 
improve upon the performance of tuberculin-based tests. Our current 
study provides strong evidence that defined peptide-based DST may 
represent promising alternatives to the traditional tuberculin-based 
assays for bTB diagnosis in field settings, and additionally provides 
the ability to differentiate infected from BCG-vaccinated animals, 
thereby overcoming a major hurdle for the implementation of BCG 
cattle vaccination programs as a key component of disease control 
in low- and middle-income countries.
Promising results of preliminary safety trials (not shown) with DST 
in Bos taurus ssp. indicus crossbred cattle under Good Laboratory 
Practice (GLP) conditions in India with repeat and overdosing exper-
iments suggest that the DST is safe. Future efforts are needed to assess 
the performance characteristics of DST in larger cohorts of infected, 
control, and BCG-vaccinated animals under field conditions to satisfy 
OIE standards for assay validation, as well as provide the scientific 
basis for implementation of the DST in national bTB surveillance 
and control programs and critically needed tools to accelerate control 
of bTB in the 21st century.
MATERIALS AND METHODS
Antigens and peptides
Commercial preparations of bovine tuberculin (PPD-B) and avian 
tuberculin (PPD-A, Thermo Fisher Scientific) were used to stimu-
late PBMCs at a final concentration of 300 and 250 IU/ml, respec-
tively, as per kit instructions. Two sets of peptides [PCL, 40-mer length 
with a 20-residue overlap; PCS (peptide cocktail–short), 16 to 20 mers 
with an 8- to 12-residue overlap] were chemically synthesized to a 
minimal purity of 98 and 85%, respectively. The identity was con-
firmed by mass spectrometry (see table S1 for amino acid sequences). 
A histidine- tagged fusion recombinant protein of ESAT-6, CFP-10, and 
Rv3615c, expressed in Escherichia coli, was purified by nickel affin-
ity chromatography (Lionex Ltd., Braunschweig, Germany).
Animals
For the in vitro experiments conducted at Animal and Plant Health 
Agency (APHA), archived PBMCs from the following groups of cattle 
(B. taurus) were used: (i) naturally M. bovis–infected cattle originating 
from U.K. herds known to have bTB (natural infection was confirmed 
by postmortem and/or culture analysis), (ii) noninfected control cattle 
originating from U.K. herds in the low risk area that were officially 
tuberculosis free for more than 5 years, and (iii) BCG vaccinates 
consisting of control cattle as described in (ii) that were subsequently 
vaccinated with BCG Danish Statens Serum Institut (SSI) (equivalent 
to five human doses). PBMCs from 8 weeks after vaccination were 
used. For in vivo testing of the peptide cocktails, the following groups 
of cattle were used: (i) experimentally M. bovis–infected cattle con-
sisting of male calves experimentally infected with approximately 
10,000 colony-forming units of a field strain of M. bovis (AF2122/97) 
via the endobronchial route (skin tests were performed 5 weeks after 
infection, and infection was confirmed by postmortem and/or cul-
ture analysis), and (ii) noninfected control cattle as described above. 
Last, to determine performance characteristics of the DST in endemic 
country settings, in vivo sensitivity of the peptide cocktails was also 
assessed in 25 adult crossbred cattle (Holstein Friesian X Zebu) in 
Ethiopia. These cattle were initially recruited from the Holeta Na-
tional Dairy Research Center of the Ethiopian Institute of Agricultural 
Research as they were positive for bTB and gave strong positive re-
sponses to both SICCT and IGRA. All cattle experiments were per-
formed in accordance with animal ethics and biosafety protocols 
approved by the Aklilu Lemma Institute of Pathobiology Review 
Board (reference no. ALIPB IBR/007/2011/2018). Animal procedures 
for studies conducted at APHA were approved by the APHA Animal 
Welfare and Ethical Review Body and in Ethiopia by the Addis Ababa 
University Ethics Review Committee.
Skin test procedures
PPD-A and PPD-B were administered in a 0.1-ml volume as per the 
manufacturer’s recommendations, while peptides were administered 
as a cocktail containing 10 g of each peptide (0.1-ml final volume) 
based on previously established dose titration experiments performed 
by skin testing cattle (27). Skin thicknesses were measured by the 
same operator before and at 72 hours after administration, and the 
difference in skin thickness (in millimeters) between the pre- and post- 
skin test readings was recorded as per OIE-prescribed guidelines (19).
In vitro stimulation of PBMCs
The PBMC preparation was performed following the “overlay” method 
using tubes without frit and cryopreserved. Thawing of cryopreserved 
cells was performed as quickly as possible in a water bath at 37°C. Upon 
thawing, appropriate volume of complete medium [RPMI 1640 con-
taining 2 mM GlutaMax, 25 mM Hepes, 0.1 mM NEAA (nonessential 
amino acids), 5 × 10−5 M -mercaptoethanol, penicillin (100 U/ml), 
streptomycin (100 g/ml) (Gibco Life Technologies, UK), and 10% fetal 
calf serum (Sigma-Aldrich, UK)] was added in a drop-by-drop man-
ner and centrifuged at 350g for 10 min at room temperature. The super-
natant was carefully discarded, and the cell pellet was gently loosened, 
following which it was resuspended in an appropriate volume of fresh 
complete medium depending on the required concentration for the 
assay. Cells were counted using a hemocytometer and incubated with 
the antigens for in vitro stimulation. For ELISpot/FluoroSpot, following 
an incubation period of ~20 hours, the spots were developed as de-
scribed below. For BOVIGAM, the incubation period was 3 to 5 days, 
after which the plates were centrifuged at 350g for 10 min at room 
temperature and the supernatant was carefully harvested.
IFN- enzyme-linked immunosorbent assay
IFN- concentrations in PBMC culture supernatants were deter-
mined using the commercially available BOVIGAM enzyme-linked 
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immunosorbent assay–based kits (Thermo Fisher Scientific, USA). 
Results were initially expressed as the optical density at 450 nm 
(OD450) for cultures stimulated with antigen minus the OD450 for cul-
tures without antigen (i.e., OD450). The results from antigen dose 
titration curves allowed AUC values to be calculated using Prism 7 
(GraphPad Software, La Jolla, CA) software.
IFN- ELISpot/FluoroSpot assay
Stimulation of PBMCs for these assays was performed as previously 
described (40). The production of IFN- by PBMCs was detected 
using either (i) a secondary biotinylated antibody followed by incu-
bation with streptavidin-linked horseradish peroxidase (Bovine IFN- 
ELISpot kit; Mabtech, Stockholm, Sweden), with visualization using 
an AEC chromogen kit (Sigma, St. Louis, MO) and spot-forming units 
counted using an AID ELISPOT reader and ELISpot 4.0 software 
(Autoimmun Diagnostika, Germany), or (ii) a secondary BAM- 
conjugated anti-bovine IFN- antibody (clone MT307, Mabtech) 
followed by incubation with a fluorophore-labeled anti–BAM-490 
(Mabtech) antibody, with visualization using a fluorescence en-
hancer (Mabtech). Spot-forming units were counted using an ELISpot/ 
FluoroSpot reader system (iSpot Spectrum, AID, Germany) with soft-
ware version 7.0. The average response elicited in an individual 
animal to a particular protein was calculated as a way of normaliz-
ing within each animal. The statistical difference between these 
average responses and the individual peptide responses in all ani-
mals was determined using z scores. Z score helped determine SDs of 
the raw scores of individual peptides (number of IFN-–positive spots) 
from the average response per animal, and the results were mapped 
as shown in Fig. 2. For example, ELISPOT reader counted 99, 74, 268, 
and 296 spots for EL1, EL2, EL3, and EL4, respectively, for animal 
no. 1 (mean response elicited by animal no. 1 for ESAT-6 is 184.25). 
Z scores were found to be −2.4, −10.9, 7.2, and 3.2 for EL1, EL2, EL3, 
and EL4, respectively. A schematic representation of the approach 
is presented in fig. S4 and shows that the greater the z score, the stronger 
the individual peptide response relative to the average response elicited 
by the animal.
Statistical analysis
All statistical analyses were performed using Prism 7 (GraphPad 
Software, La Jolla, CA).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/5/7/eaax4899/DC1
Table S1. All short and long peptides used in the study are listed and sequences are provided.
Fig. S1. PPD-B responses in the IGRA.
Fig. S2. Comparison of performance of PCL with PC-1 in IGRA.
Fig. S3. Skin test responses in field reactors.
Fig. S4. Schematic representation of the approach to identify the dominant peptides based on 
overall responder frequency for the peptide cocktails.
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